Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer

KOHJI OKADA, TATSUO SHIMURA, TAKETOSHI SUEHIRO, ERITO MOCHIKI and HIROYUKI KUWANO
Anticancer Research March 2006, 26 (2B) 1369-1376;
KOHJI OKADA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: okako@med.gunma-u.ac.jp
TATSUO SHIMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKETOSHI SUEHIRO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERITO MOCHIKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI KUWANO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 26 no. 2B 1369-1376
PubMed 
16619546

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received December 27, 2005
  • Accepted February 8, 2006
  • Published online March 1, 2006.

Copyright & Usage 
Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. KOHJI OKADA,
  2. TATSUO SHIMURA,
  3. TAKETOSHI SUEHIRO,
  4. ERITO MOCHIKI and
  5. HIROYUKI KUWANO
  1. Department of General Surgical Science (Surgery 1), Gunma University, Graduate School of Medicine, Maebashi 371-8511, Japan
  1. Correspondence to: Kohji Okada, MD, Department of General Surgical Science (Surgery 1), Gunma University, Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan. Tel: +81-272-20-8224, Fax: +81-272-20-8230, e-mail: okako{at}med.gunma-u.ac.jp

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 26 (2B)
Anticancer Research
Vol. 26, Issue 2B
March-April 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer
KOHJI OKADA, TATSUO SHIMURA, TAKETOSHI SUEHIRO, ERITO MOCHIKI, HIROYUKI KUWANO
Anticancer Research Mar 2006, 26 (2B) 1369-1376;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer
KOHJI OKADA, TATSUO SHIMURA, TAKETOSHI SUEHIRO, ERITO MOCHIKI, HIROYUKI KUWANO
Anticancer Research Mar 2006, 26 (2B) 1369-1376;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Elevated soluble Galectin-3 as a marker of chemotherapy efficacy in Breast cancer patients; a prospective study
  • Expression levels of {beta}-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study
  • Effect of Long Interval Between Hyperthermochemoradiation Therapy and Surgery for Rectal Cancer on Apoptosis, Proliferation and Tumor Response
  • Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
  • Google Scholar

More in this TOC Section

  • Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer
  • Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
  • Rare Upper Mediastinal Oligometastasis from Early Esophagogastric Adenocarcinoma: A Case Report
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire